A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Recruiting · NCT07681089 · Interventional (participants receive a specific treatment) · Lead sponsor: Kiminori Kimura, MD
View the official record on ClinicalTrials.gov →Interventions studied
Foscenvivint
What this trial is about
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Who can take part
Age range
18 Years to 79 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with hemophilia and liver cirrhosis caused by HIV/HCV co-infection who meet both of the following criteria:
- Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA maintained at \<200 copies/mL and a CD4-positive T lymphocyte count of ≥200 cells/µL at screening.
- Patients with HCV infection who have achieved sustained virologic response (SVR) at least 12 months before registration.
- Patients with Child-Pugh class A or B liver cirrhosis (Child-Pugh score 5-9).
- Patients who meet at least one of the following criteria for the diagnosis of liver cirrhosis:
- <!-- -->
- Liver stiffness measurement by FibroScan of ≥12.5 kPa, corresponding to fibrosis stage F4, at screening.
- Abdominal CT showing changes in liver morphology and/or findings suggestive of portal hypertension.
- Patients with an Eastern Cooperative Oncology Group Performance Status of 0-2.
Exclusion criteria
- Patients with liver cirrhosis caused by etiologies other than HCV or of unknown etiology.
- Patients with esophageal or gastric varices judged by endoscopic examination at screening to require treatment.
- Patients with current malignancy or a history of malignancy within 3 years before registration.
- Patients who have undergone liver transplantation or other organ transplantation, including bone marrow transplantation.
- Patients with active AIDS-defining disease requiring treatment. -
Where it is running
3 locations listed.
- Hokkaido University Hospital - Sapporo, Hokkaido, Japan
- National Hospital Organization Osaka National Hospital - Osaka, Osaka, Japan
- Tokyo Metropolitan Komagome Hospital - Bunkyo-Ku, Tokyo, Japan